By Melanie Senior
AstraZeneca PLC may have come late to the in-licensing game, but it arrived with a flourish in December 2005,...
Much of AstraZeneca's newly-in-licensed bounty is high-risk. But it provides a low-cost pipeline boost, and marks a sharp turnaround at the firm.
By Melanie Senior
AstraZeneca PLC may have come late to the in-licensing game, but it arrived with a flourish in December 2005,...
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.